The evolving field of theranostics is poised to broaden treatment options for millions of cancer patients, according to one GE Healthcare leader.

“Theranostics is the combination of diagnostics and therapy — but it’s much deeper than that,” said Sergio Calvo, global general manager of theranostics at GE Healthcare, during an interview at the Radiological Society of North America ’s annual conference last week in Chicago.

Calvo defined theranostics as a targeted therapy approach that uses molecular imaging to visualize the same biological target that the drug is designed to treat. Essentially, doctors scan for a molecular marker on cancer cells and then deliver a drug that binds to that receptor, allowing them to see and treat the disease in a connected loop.

Theranostics isn’t brand

See Full Page